KalVista Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: KALV · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
Related Tickers: KALV
TL;DR
KALV filed an 8-K for shareholder votes - standard procedure.
AI Summary
KalVista Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions, but it is a standard procedural filing.
Why It Matters
This filing indicates that KalVista Pharmaceuticals held a meeting or took action requiring a vote from its shareholders, a common corporate governance event.
Risk Assessment
Risk Level: low — This is a routine procedural filing related to corporate governance and does not appear to contain new material financial or operational information.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- 0000950170-24-112904 (filing_id) — Accession Number
- October 03, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36830 (commission_file_number) — SEC File Number
- 20-0915291 (irs_number) — IRS Employer Identification No.
- 55 Cambridge Parkway Suite 901E (address) — Principal Executive Offices
- Cambridge (city) — Principal Executive Offices
- Massachusetts (state) — Principal Executive Offices
- 02142 (zip_code) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of KalVista Pharmaceuticals' security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 03, 2024.
What is KalVista Pharmaceuticals' state of incorporation?
KalVista Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SEC file number for KalVista Pharmaceuticals?
The SEC file number for KalVista Pharmaceuticals is 001-36830.
Where are KalVista Pharmaceuticals' principal executive offices located?
KalVista Pharmaceuticals' principal executive offices are located at 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-10-04 16:05:46
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
Filing Documents
- kalv-20241003.htm (8-K) — 56KB
- 0000950170-24-112904.txt ( ) — 167KB
- kalv-20241003.xsd (EX-101.SCH) — 24KB
- kalv-20241003_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On October 3, 2024, KalVista Pharmaceuticals, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders (" Annual Meeting ") and the following proposals were adopted: 1. Election of two Class III directors, William Fairey and Nancy Stuart (each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified): Nominees Shares For Shares Against Shares Abstaining Broker Non-Votes William Fairey 30,169,349 872,398 33,171 8,328,823 Nancy Stuart 19,324,277 11,717,484 33,157 8,328,823 2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025: Shares For Shares Against Shares Abstaining Broker Non-Votes 39,323,443 46,858 33,440 0 3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 26,578,805 4,459,363 36,750 8,328,823
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: October 4, 2024 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer